Literature DB >> 9153283

Identification of naturally processed T cell epitopes from glutamic acid decarboxylase presented in the context of HLA-DR alleles by T lymphocytes of recent onset IDDM patients.

J Endl1, H Otto, G Jung, B Dreisbusch, F Donie, P Stahl, R Elbracht, G Schmitz, E Meinl, M Hummel, A G Ziegler, R Wank, D J Schendel.   

Abstract

Glutamic acid decarboxylase (GAD) has been defined as a major target antigen in insulin-dependent diabetes mellitus (IDDM). To identify the molecular ligands triggering a T cell response to GAD, a panel of human GAD65-specific T lymphocyte lines was generated from peripheral blood of three recent onset IDDM patients. All lines derived from a patient expressing the high-risk-conferring HLA-DR*0301/ *0401 haplotypes recognized a single epitope localized between amino acid positions 270 and 283 of GAD65, a stretch that is located in close proximity to the homology region shared with Coxsackie virus P2-C protein. All lines with this specificity were restricted to the DRA, B1*0401 product of the DR4 haplotype. Analysis of the GAD-specific T cell response in a second patient homozygous for DR4 haplotypes demonstrated that the same DRA, B1*0401 allele selected T cells specific for a different determinant. The T cell response profile in a third patient showed that DR*1501/ *1601-encoding haplotypes could present at least three different epitopes to GAD65-specific T lymphocytes. One of these epitopes was presented by a DR allele associated with the resistance-conferring DRB1*1501 haplotype. GAD-specific T cell lines could not be isolated from HLA class II-matched normal individuals. Our data reveal that (a) the T cell response to GAD65 is quite heterogenous in recent onset IDDM patients; (b) HLA-DR, not DQ, seems to be the principal restriction element used by T cells present at the onset of the disease; and (c) T cells responding to epitopes containing identical sequences to Coxsackie virus P2-C protein were not detected.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9153283      PMCID: PMC508080          DOI: 10.1172/JCI119423

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Epitope analysis with monoclonal antibodies directed against class II molecules subdivides HLA-DR2, DR3 and DR4: correlations with cellularly defined Dw specificities.

Authors:  J P Johnson; H Nordwig; R Wank
Journal:  Tissue Antigens       Date:  1987-01

2.  The complete nucleotide sequence of coxsackievirus B4 and its comparison to other members of the Picornaviridae.

Authors:  O Jenkins; J D Booth; P D Minor; J W Almond
Journal:  J Gen Virol       Date:  1987-07       Impact factor: 3.891

3.  L-Glutamate decarboxylase from brain.

Authors:  J Y Wu; L Denner; C T Lin; G X Song
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

4.  Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies.

Authors:  G F Bottazzo; A Florin-Christensen; D Doniach
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

5.  Coxsackie virus B4 produces transient diabetes in nonhuman primates.

Authors:  J W Yoon; W T London; B L Curfman; R L Brown; A L Notkins
Journal:  Diabetes       Date:  1986-06       Impact factor: 9.461

6.  Naturally processed T cell epitopes from human glutamic acid decarboxylase identified using mice transgenic for the type 1 diabetes-associated human MHC class II allele, DRB1*0401.

Authors:  L S Wicker; S L Chen; G T Nepom; J F Elliott; D C Freed; A Bansal; S Zheng; A Herman; A Lernmark; D M Zaller; L B Peterson; J B Rothbard; R Cummings; P J Whiteley
Journal:  J Clin Invest       Date:  1996-12-01       Impact factor: 14.808

7.  Evidence for a long prediabetic period in type I (insulin-dependent) diabetes mellitus.

Authors:  A N Gorsuch; K M Spencer; J Lister; J M McNally; B M Dean; G F Bottazzo; A G Cudworth
Journal:  Lancet       Date:  1981 Dec 19-26       Impact factor: 79.321

8.  Antibodies to a 64,000 Mr human islet cell antigen precede the clinical onset of insulin-dependent diabetes.

Authors:  S Baekkeskov; M Landin; J K Kristensen; S Srikanta; G J Bruining; T Mandrup-Poulsen; C de Beaufort; J S Soeldner; G Eisenbarth; F Lindgren
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

9.  Cellular immune response to diverse islet cell antigens in IDDM.

Authors:  I Durinovic-Bellò; M Hummel; A G Ziegler
Journal:  Diabetes       Date:  1996-06       Impact factor: 9.461

10.  [The glutamic acid decarboxylase (GAD) antibodies and their clinical significance].

Authors:  K Ogata; K Ohta; H Kubo; A Yamaguchi; H Watanabe
Journal:  Rinsho Byori       Date:  1995-05
View more
  31 in total

1.  Selecting culprits in type 1 diabetes beta-cell killing.

Authors:  A Lernmark
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 2.  Genetic predisposition to IDDM.

Authors:  S Caillat-Zucman; J F Bach
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 3.  T-cell reactivity to beta-cell antigens in human insulin-dependent (type 1) diabetes mellitus. Implications for diagnosis and therapy.

Authors:  B O Roep
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 4.  DR, DQ, and you: MHC alleles and autoimmunity.

Authors:  G Sønderstrup; H O McDevitt
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

Review 5.  Prospects for the prevention and reversal of type 1 diabetes mellitus.

Authors:  Nikolai Petrovsky; Diego Silva; Desmond A Schatz
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  GAD antigen and its significance in type I diabetes.

Authors:  M I Hawa; R D G Leslie
Journal:  J Endocrinol Invest       Date:  2002 Jul-Aug       Impact factor: 4.256

7.  Characterization of CD4+ T cells specific for glutamic acid decarboxylase (GAD65) and proinsulin in a patient with stiff-person syndrome but without type 1 diabetes.

Authors:  Arno Hänninen; Merja Soilu-Hänninen; Christiane S Hampe; Angie Deptula; Kelly Geubtner; Jorma Ilonen; Mikael Knip; Helena Reijonen
Journal:  Diabetes Metab Res Rev       Date:  2010-05       Impact factor: 4.876

8.  Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders.

Authors:  A C Powers; K Bavik; J Tremble; K Daw; W A Scherbaum; J P Banga
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 9.  Animal models have little to teach us about type 1 diabetes: 1. In support of this proposal.

Authors:  B O Roep; M Atkinson
Journal:  Diabetologia       Date:  2004-10-13       Impact factor: 10.122

10.  Improved in planta expression of the human islet autoantigen glutamic acid decarboxylase (GAD65).

Authors:  Linda Avesani; Alberto Falorni; Giovanni Battista Tornielli; Carla Marusic; Andrea Porceddu; Annalisa Polverari; Claudia Faleri; Filippo Calcinaro; Mario Pezzotti
Journal:  Transgenic Res       Date:  2003-04       Impact factor: 2.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.